<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789917</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE MucT003-16</org_study_id>
    <nct_id>NCT02789917</nct_id>
  </id_info>
  <brief_title>APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF</brief_title>
  <acronym>APPROACH</acronym>
  <official_title>APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helmholtz Zentrum München</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesised that a dual therapy strategy by oral anticoagulation with the new
      Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with
      phenprocoumon plus acetylsalicylic acid (ASA) and clopidogrel with respect to avoiding
      bleeding events in patients with atrial fibrillation undergoing percutaneous coronary
      intervention in the setting of an acute coronary syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with atrial fibrillation (AF) presenting an acute coronary syndrome (ACS) and
      undergoing PCI require a triple therapy with a combination of oral anticoagulation (OAC) and
      dual anti-platelet therapy. Current guidelines recommend a regimen consisting of aspirin,
      clopidogrel and an oral anticoagulant. Although effective in preventing recurrent ischemia,
      triple therapy confers an elevated bleeding risk, which also has a major impact on the
      patients' prognosis and survival. Data from one randomized trial suggest that omitting
      aspirin in patients with indication for triple therapy may reduce the risk of bleeding
      without an increase of the rate of ischemic events. In addition, the recently introduced
      non-vitamin-K oral anticoagulants (NOACs) show less bleeding events as compared to vitamin-K
      antagonist in AF patients. In this trial it is postulated that a dual therapy consisting of
      the factor-Xa inhibitor apixaban and clopidogrel is associated with significant lower
      bleeding rates as compared to traditional triple therapy with aspirin, clopidogrel and a
      vitamin K antagonist (VKA). To test this hypothesis, patients with atrial fibrillation, who
      underwent PCI in the setting of an ACS will be randomized to either a dual therapy
      (apixaban+clopidogrel) or a triple therapy (aspirin+clopiodgrel+VKA). The patients will be
      followed-up for 6 months after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The combined endpoint of moderate or major bleeding complications during the initial hospitalization and follow up (Bleeding Academic Research Consortium (BARC) type ≥ 2 bleeding)</measure>
    <time_frame>up to 6 months after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined event of death, myocardial infarction, definite stent thrombosis, stroke/other systemic thromboembolism and all the individual components of the composite secondary endpoint</measure>
    <time_frame>up to 6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications (Major bleeding: BARC &gt; 3b bleeding)</measure>
    <time_frame>up to 6 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Dual therapy (incl. NOAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban plus Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple therapy (incl. VKA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phrenprocoumon plus Clopidogrel plus ASA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dual Therapy</intervention_name>
    <description>Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.</description>
    <arm_group_label>Dual therapy (incl. NOAC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Triple Therapy</intervention_name>
    <description>HAS-BLED-Score &lt;3:
Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.
HAS-BLED-Score ≥ 3:
Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months.</description>
    <arm_group_label>Triple therapy (incl. VKA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Patients with an ACS after successful percutaneous coronary intervention

          -  Indication for oral anticoagulation due to non-valvular atrial fibrillation or atrial
             flutter (CHA2DS2VASc score ≥ 2)

          -  Males and Females, ages ≥ 18

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             the start of study drug.

          -  Women must not be breastfeeding

          -  WOCBP must agree to follow instructions for method(s) of contraception for the
             duration of treatment with study drugs plus 30 days (duration of ovulatory cycle)
             post-treatment completion. However they must still undergo pregnancy testing.

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  History of intracranial bleeding

          -  Active bleeding

          -  History of TIMI major bleeding according to TIMI and/or type ≥3b BARC criteria in the
             last 6 months

          -  History of peptic ulcer in the last 6 months

          -  Subjects with a history of a complicated or prolonged cardiogenic shock in the last
             two weeks prior to randomization. A complicated or prolonged cardiogenic shock is
             defined by a cardiogenic shock that required mechanical ventilation or the
             cardiovascular support with positive inotropic drugs (i.v. catecholamine) for ≥7 days

          -  Planned major surgery during the study course with planned discontinuation of
             antithrombotic therapy

          -  Expected life expectancy of less than a year and/or severe illness (e.g. malignancy)

          -  Mechanical valve replacement

          -  Valvular atrial fibrillation

          -  Severe renal insufficiency (creatinine clearance &lt; 30ml/min)

          -  Severe liver insufficiency (Child-Pugh-class C) or elevated hepatic transaminases &gt;2
             times the upper limit of normal

          -  Patient's inability to fully comply with the study protocol

          -  Known or persistent abuse of medication, drugs or alcohol reliable by the investigator
             in individual cases

          -  Subjects with known contraindications to apixaban, phenprocoumon, clopidogrel or ASA
             treatment, which are hypersensitive to the drug substance or any component of the
             product

          -  Relevant hematologic deviations: platelet count &lt; 50 G/L or platelet count &gt; 600 G/L

          -  Current or planned pregnancy or nursing women, women 90 days after childbirth. Females
             of childbearing potential, who do not use and are not willing to use medically
             reliable methods of contraception for the entire study duration (such as oral,
             injectable, or implantable contraceptives, or intrauterine contraceptive devices)
             unless they are surgically sterilized / hysterectomized or there are any other
             criteria considered sufficiently
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Wakili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München (LMU)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Massberg, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Universität München (LMU)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reza Wakili, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>73036</phone_ext>
    <email>reza.wakili@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Riesinger, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>0</phone_ext>
    <email>Lisa.Riesinger@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Munich University Hospital</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Wakili, MD</last_name>
      <phone>+49894400</phone>
      <phone_ext>73036</phone_ext>
      <email>reza.wakili@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Maria Riesinger, MD</last_name>
      <phone>+49894400</phone>
      <phone_ext>0</phone_ext>
      <email>Lisa_Maria.Riesinger@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Herzzentrum am Universitätsklinikum</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UKHS Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Augustinum</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München-Neuperlach</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Reza Wakili</investigator_full_name>
    <investigator_title>PD Dr. med. Reza Wakili</investigator_title>
  </responsible_party>
  <keyword>ACS</keyword>
  <keyword>Triple-Therapy</keyword>
  <keyword>AF</keyword>
  <keyword>oral anticoagulation (OAC)</keyword>
  <keyword>non-vitamin-K oral anticoagulant (NOAC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Phenprocoumon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Inclusion in central DZHK Database (German Centre for Cardiovascular Research)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

